Job title: CMO, Essa Pharma & Director
Alessandra Cesano, MD, PhD has recently joined ESSA as Chief Medical Officer.
Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance.
Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals.
Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania.
She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group.
Live Q&A With Your Expert Speakers 11:20 am
Use this opportunity to ask your expert speakers those burning questions!Read more
day: Day One
Reprogramming the Tumor Microenvironment Metabolism to Enhance Adoptive Cell Therapy Efficacy in Solid Tumors 10:05 am
Review the field’s current understanding of the different metabolic TME barriers to effective ACT in solid tumors Discuss new technology platforms allowing the profiling of these metabolic TME immuno-suppressive mechanisms Discuss novel therapeutic strategies to modulate the TME metabolism to improve CAR-T trafficking, function and persistence in solid tumorsRead more
day: Day One